A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 20, 2023

Primary Completion Date

May 30, 2026

Study Completion Date

December 31, 2026

Conditions

Thyroid Eye Disease, TED

Interventions

DRUG

IBI311

The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W

Trial Locations (1)

Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY